162 related articles for article (PubMed ID: 27450228)
1. Physiologically Based Absorption Modeling to Explore the Impact of Food and Gastric pH Changes on the Pharmacokinetics of Alectinib.
Parrott NJ; Yu LJ; Takano R; Nakamura M; Morcos PN
AAPS J; 2016 Nov; 18(6):1464-1474. PubMed ID: 27450228
[TBL] [Abstract][Full Text] [Related]
2. Physiologically Based Absorption Modelling to Explore the Impact of Food and Gastric pH Changes on the Pharmacokinetics of Entrectinib.
Parrott N; Stillhart C; Lindenberg M; Wagner B; Kowalski K; Guerini E; Djebli N; Meneses-Lorente G
AAPS J; 2020 May; 22(4):78. PubMed ID: 32458089
[TBL] [Abstract][Full Text] [Related]
3. Effect of Food and Esomeprazole on the Pharmacokinetics of Alectinib, a Highly Selective ALK Inhibitor, in Healthy Subjects.
Morcos PN; Guerini E; Parrott N; Dall G; Blotner S; Bogman K; Sturm C; Balas B; Martin-Facklam M; Phipps A
Clin Pharmacol Drug Dev; 2017 Jul; 6(4):388-397. PubMed ID: 27545320
[TBL] [Abstract][Full Text] [Related]
4. Model-Based Assessments of CYP-Mediated Drug-Drug Interaction Risk of Alectinib: Physiologically Based Pharmacokinetic Modeling Supported Clinical Development.
Cleary Y; Gertz M; Morcos PN; Yu L; Youdim K; Phipps A; Fowler S; Parrott N
Clin Pharmacol Ther; 2018 Sep; 104(3):505-514. PubMed ID: 29226313
[TBL] [Abstract][Full Text] [Related]
5. Effect of Hepatic Impairment on the Pharmacokinetics of Alectinib.
Morcos PN; Cleary Y; Sturm-Pellanda C; Guerini E; Abt M; Donzelli M; Vazvaei F; Balas B; Parrott N; Yu L
J Clin Pharmacol; 2018 Dec; 58(12):1618-1628. PubMed ID: 30052269
[TBL] [Abstract][Full Text] [Related]
6. Absorption, distribution, metabolism and excretion (ADME) of the ALK inhibitor alectinib: results from an absolute bioavailability and mass balance study in healthy subjects.
Morcos PN; Yu L; Bogman K; Sato M; Katsuki H; Kawashima K; Moore DJ; Whayman M; Nieforth K; Heinig K; Guerini E; Muri D; Martin-Facklam M; Phipps A
Xenobiotica; 2017 Mar; 47(3):217-229. PubMed ID: 27180975
[TBL] [Abstract][Full Text] [Related]
7. Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases.
Kodama T; Hasegawa M; Takanashi K; Sakurai Y; Kondoh O; Sakamoto H
Cancer Chemother Pharmacol; 2014 Nov; 74(5):1023-8. PubMed ID: 25205428
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the effect of food and gastric pH on the single-dose pharmacokinetics of cabozantinib in healthy adult subjects.
Nguyen L; Holland J; Mamelok R; Laberge MK; Grenier J; Swearingen D; Armas D; Lacy S
J Clin Pharmacol; 2015 Nov; 55(11):1293-302. PubMed ID: 25907407
[TBL] [Abstract][Full Text] [Related]
9. Ribociclib Bioavailability Is Not Affected by Gastric pH Changes or Food Intake: In Silico and Clinical Evaluations.
Samant TS; Dhuria S; Lu Y; Laisney M; Yang S; Grandeury A; Mueller-Zsigmondy M; Umehara K; Huth F; Miller M; Germa C; Elmeliegy M
Clin Pharmacol Ther; 2018 Aug; 104(2):374-383. PubMed ID: 29134635
[TBL] [Abstract][Full Text] [Related]
10. Physiologically-based pharmacokinetic model for alectinib, ruxolitinib, and panobinostat in the presence of cancer, renal impairment, and hepatic impairment.
Alsmadi MM; Al-Daoud NM; Jaradat MM; Alzughoul SB; Abu Kwiak AD; Abu Laila SS; Abu Shameh AJ; Alhazabreh MK; Jaber SA; Abu Kassab HT
Biopharm Drug Dispos; 2021 Jun; 42(6):263-284. PubMed ID: 33904202
[TBL] [Abstract][Full Text] [Related]
11. Effect of gastric pH on the pharmacokinetics of a BCS class II compound in dogs: utilization of an artificial stomach and duodenum dissolution model and GastroPlus,™ simulations to predict absorption.
Bhattachar SN; Perkins EJ; Tan JS; Burns LJ
J Pharm Sci; 2011 Nov; 100(11):4756-65. PubMed ID: 21681753
[TBL] [Abstract][Full Text] [Related]
12. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.
Gadgeel SM; Gandhi L; Riely GJ; Chiappori AA; West HL; Azada MC; Morcos PN; Lee RM; Garcia L; Yu L; Boisserie F; Di Laurenzio L; Golding S; Sato J; Yokoyama S; Tanaka T; Ou SH
Lancet Oncol; 2014 Sep; 15(10):1119-28. PubMed ID: 25153538
[TBL] [Abstract][Full Text] [Related]
13. Use of Gastrointestinal Simulator, Mass Transport Analysis, and Absorption Simulation to Investigate the Impact of pH Modifiers in Mitigating Weakly Basic Drugs' Performance Issues Related to Gastric pH: Palbociclib Case Study.
Kuminek G; Salehi N; Waltz NM; Sperry DC; Greenwood DE; Hate SS; Amidon GE
Mol Pharm; 2023 Jan; 20(1):147-158. PubMed ID: 36367432
[TBL] [Abstract][Full Text] [Related]
14. Absolute bioavailability and effect of formulation change, food, or elevated pH with rabeprazole on cobimetinib absorption in healthy subjects.
Musib L; Choo E; Deng Y; Eppler S; Rooney I; Chan IT; Dresser MJ
Mol Pharm; 2013 Nov; 10(11):4046-54. PubMed ID: 24010577
[TBL] [Abstract][Full Text] [Related]
15. Antitumor activity of alectinib, a selective ALK inhibitor, in an ALK-positive NSCLC cell line harboring G1269A mutation: Efficacy of alectinib against ALK G1269A mutated cells.
Yoshimura Y; Kurasawa M; Yorozu K; Puig O; Bordogna W; Harada N
Cancer Chemother Pharmacol; 2016 Mar; 77(3):623-8. PubMed ID: 26849637
[TBL] [Abstract][Full Text] [Related]
16. Alectinib for the treatment of ALK-positive stage IV non-small cell lung cancer.
Wong KM; Noonan S; O'Bryant C; Jimeno A
Drugs Today (Barc); 2015 Mar; 51(3):161-70. PubMed ID: 25876560
[TBL] [Abstract][Full Text] [Related]
17. In vitro dissolution methodology, mini-Gastrointestinal Simulator (mGIS), predicts better in vivo dissolution of a weak base drug, dasatinib.
Tsume Y; Takeuchi S; Matsui K; Amidon GE; Amidon GL
Eur J Pharm Sci; 2015 Aug; 76():203-12. PubMed ID: 25978875
[TBL] [Abstract][Full Text] [Related]
18. Clinical Efficacy of Alectinib in Patients with
Oya Y; Yoshida T; Kuroda H; Shimizu J; Horio Y; Sakao Y; Hida T; Yatabe Y
Anticancer Res; 2017 Nov; 37(11):6477-6480. PubMed ID: 29061835
[TBL] [Abstract][Full Text] [Related]
19. Assessment of drug-drug interaction potential between ceritinib and proton pump inhibitors in healthy subjects and in patients with ALK-positive non-small cell lung cancer.
Lau YY; Gu W; Lin T; Viraswami-Appanna K; Cai C; Scott JW; Shi M
Cancer Chemother Pharmacol; 2017 Jun; 79(6):1119-1128. PubMed ID: 28424965
[TBL] [Abstract][Full Text] [Related]
20. Utilizing In Vitro Dissolution-Permeation Chamber for the Quantitative Prediction of pH-Dependent Drug-Drug Interactions with Acid-Reducing Agents: a Comparison with Physiologically Based Pharmacokinetic Modeling.
Zhu AZ; Ho MD; Gemski CK; Chuang BC; Liao M; Xia CQ
AAPS J; 2016 Nov; 18(6):1512-1523. PubMed ID: 27600136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
